Health Impact Study of Aquatabs in Tamale, Ghana
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00252928|
Recruitment Status : Completed
First Posted : November 15, 2005
Last Update Posted : October 30, 2007
|Condition or disease||Intervention/treatment||Phase|
|Diarrhea||Other: Sodium dichloroisocyanurate (NaDCC) tablets Other: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||240 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Health Impact Study of a Water Treatment Tablet, Aquatabs, in Tamale, Ghana|
|Study Start Date :||July 2006|
|Actual Study Completion Date :||November 2006|
Placebo Comparator: A
Placebo group does not receive Aquatabs.
Intervention arms receives Aquatabs.
Other: Sodium dichloroisocyanurate (NaDCC) tablets
Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
Other Name: Aquatabs
- Measure the impact of Aquatabs on diarrhea among persons in households in Tamale, Ghana. [ Time Frame: 12 weeks ]
- Assess the microbiological quality of household water among persons living in Tamale, Ghana. [ Time Frame: 12 weeks ]
- Determine the acceptability of Aquatabs. [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252928
|United States, Georgia|
|Emory University Center for Global Safe Water|
|Atlanta, Georgia, United States, 30322|
|University of Development Studies|
|Principal Investigator:||Seema Jain, MD||Centers for Disease Control and Prevention|
|Principal Investigator:||Robert Quick, MD||Centers for Disease Control and Prevention|